Shattuck Labs, Inc.

– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn's disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis suppurativa; trial initiation expected in the fourth quarter of 2026 – – Presented preclinical data for SL-846 at UEG Week 2026, including data from a chronic toxicology study in non-human primates – AUSTIN, Texas and DURHAM, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, …

Shattuck Labs (NASDAQ: STTK - Get Free Report) and Exicure (NASDAQ: XCUR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability. Risk and Volatility Shattuck Labs has a beta

AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona,…

Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) shares fell 5.3% during mid-day trading on Monday. The company traded as low as $6.33 and last traded at $6.3760. 599,094 shares traded hands during mid-day trading, a decline of 37% from the average session volume of 954,866 shares. The stock had previously closed at $6.73. Wall

Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report)'s stock price traded up 11.9% on Wednesday. The stock traded as high as $6.89 and last traded at $7.3150. 221,063 shares were traded during mid-day trading, a decline of 76% from the average session volume of 928,544 shares. The stock had previously closed at $6.54. Analyst Ratings

Shattuck Labs (NASDAQ: STTK - Get Free Report) and MDxHealth (NASDAQ: MDXH - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends. Risk and Volatility Shattuck Labs has a beta

–   RECEPTIVE-HS1 Phase 2 clinical trial in patients with moderate to severe hidradenitis suppurativa (HS) expected to initiate in 2026; data from the 16-week treatment period expected in the first half of 2028   – –   HS is the second Phase 2 indication for SL-325 and expands development beyond IBD   – –   Announces appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development; Dr. Ravichandran to lead the HS clinical development program   – –   Cash runway guidance re…

Frazier Life Sciences Management L.P. bought a new position in shares of Shattuck Labs, Inc. (NASDAQ: STTK) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,750,000 shares of the company's stock, valued at approximately $26,025,000. Frazier Life Sciences Management L.P. owned 3.74%

BlackRock Inc. purchased a new stake in Shattuck Labs, Inc. (NASDAQ: STTK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,935,810 shares of the company's stock, valued at approximately $27,315,000. BlackRock Inc. owned about 5.13% of Shattuck Labs as of its

AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:

Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing its oncology program. SL-325's Phase 1 data show strong safety, low immunogenicity (3.7% ADA rate), and durable receptor occupancy, supporting quarterly dosing potential. STTK is fully funded through Phase 2b efficacy readout, with cash runway into 2029 despite significant dilution; valuation trades at a forward price-to-book discount.

One of them initiated coverage. The company has a very promising lead drug candidate.

Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Geron (NASDAQ: GERN - Get Free Report) and Shattuck Labs (NASDAQ: STTK - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Geron and

The consensus price target hints at an 85.3% upside potential for Shattuck Labs (STTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.